Why the Reckon share price is flat on underlying NPAT up 3%

Reckon Ltd (ASX: RKN) posted its full-year 2018 (FY18) results this morning with underlying NPAT growth and a $0.03 dividend after a challenging year.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Reckon Limited (ASX: RKN) put a difficult 2018 behind it to a post a solid result in its full-year earnings (FY18) this morning.

The company increased its underlying net profit after tax (NPAT) by 3% YoY to $8.8 million despite a 6% decrease in revenue to $75.4 million during the year. The major driver was the legal (-5%) and other revenue (-23%) line items which saw Group EBITDA decline by 2% to $30.6 million.

Cloud revenue was up 8% in FY18 with ~54,000 cloud users, while management noted the continued reduction in desktop revenue due to a user-led transition towards the cloud.

The company was busy innovating during the year, launching its point-of-sale (PoS) product in 2018 and acquiring online medical practice management product, Better Clinics, in July 2018.

The group increased net assets by 19.09% to $15.60 million despite a ~$3.00 million decrease in total assets during the year. The group repaid $6.04 million of borrowings which saw a net cash outflow from financing activities of $9.43 million for the year while operating cash flow increased by $1.2 million to $10.88 million after the de-merger of its Document Management division in 2017.

In a big win for shareholders, the Board approved the reinstatement of the company's dividend policy, paying out a fully-franked $0.03 per share in September 2018, equating to a dividend yield of around 4.50%. The stock saw a steady increase in its dividend from $0.04 per share in 2006 to a peak of $0.09 (60% franked) in 2015, but business profitability saw this cut in 2016 and 2017.

The stock was up 6.06% yesterday ahead of the earnings announcement and I suspect the $0.03 dividend may not be enough to keep that price high. While the 4.48% year-to-date gain looks good on paper, in the context of a 55.47% decline since January 2018, it's clear that this is more temporary speculation than good fundamentals.

Foolish takeaway

While Reckon has posted a decent result this morning, it's a stock that has continued to slide since 2016 and is trading at a P/E multiple of 36x. The company operates in a competitive industry and has found it difficult to keep pace with technological advances.

While today's result should mitigate huge losses on the market, I'd be steering clear and looking at other Information Technology stocks including Appen Ltd (ASX: APX) or Altium Ltd (ASX: ALU).

Motley Fool contributor Lachlan Hall does not own shares in any of the companies mentioned. The Motley Fool Australia owns shares of Altium and Appen Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »